Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung transplant moms: does Baby's DNA raise rejection risk?

NCT ID NCT05689905

Knowledge-focused Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether shared genetic markers (HLA) between a child and a lung donor increase the risk of organ rejection in mothers who had a lung transplant. Researchers collected DNA from children born to 11 transplant women in France between 2012 and 2021. The goal is to better understand pregnancy-related immune risks and improve future recommendations.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could help doctors give better advice to lung transplant women about pregnancy risks.
What could go wrong
This is a small, completed study (11 participants) that only looks back at past pregnancies. It cannot prove cause and effect, and findings may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

11 people

The number who actually took part.

Started

Feb 2024

Finished

Jan 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Cohort of female lung transplant patients, a rare pathology, and their children.

Ages

1 year and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Children born between 01/01/2012 and 31/12/2021 of female patients over 18 years old with lung transplantation (mono, uni or cardio pulmonary) in France, * Alive at the time of our study. * Legal guardians' consent for oral swabbing of their child and HLA typing on this swab * Affiliated or beneficiaries of a social security system or similar Exclusion Criteria: \- Refusal of consent by the patient and/or one of the two parents

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Graft rejection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

transplant rejection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Graft rejection Lung transplantation Pregnancy

Contacts and locations

Locations

  • AP-HM

    Marseille, 13005, France

  • Bordeaux University Hospital

    Bordeaux, 33000, France

  • Civils Hospitals Lyon

    Lyon, 69002, France

  • Cochin Hospital (AP-HP)

    Paris, 75014, France

  • Foch Hospital

    Suresnes, 92150, France

  • Grenoble University Hospital

    Grenoble, 38700, France

  • Marie Lannelongue Hospital (GHSJ)

    Le Plessis-Robinson, 92350, France

  • Nantes University Hospital

    Nantes, Loire Atlantique, 44093, France

  • Strasbourg University Hospital

    Strasbourg, 67200, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.